SYMBICORT Market Insights
Key Factors Driving SYMBICORT Growth
1. Strong position in asthma and COPD maintenance therapy
SYMBICORT established itself as a leading ICS/LABA therapy through extensive clinical evidence in both asthma and COPD. The product demonstrated efficacy in reducing exacerbations, improving lung function, and supporting long-term disease control. AstraZeneca’s Phase III RISE study in COPD and CHASE pediatric asthma program further reinforced its utility across broad patient populations. The RISE study included more than 1,200 COPD patients across 10 countries, while CHASE evaluated pediatric asthma efficacy and safety.
2. Large and growing respiratory disease burden globally
Asthma and COPD remain among the world’s largest chronic disease markets. Rising air pollution, smoking exposure, urbanization, and aging populations continue driving demand for maintenance inhalers globally. SYMBICORT benefits from use in both diseases, expanding its addressable patient base compared with single-indication therapies. AstraZeneca continues to report strong growth in its Respiratory & Immunology (R&I) business, with R&I revenue increasing 22% in H1 2024 and 25% in FY2024, reflecting sustained respiratory franchise momentum.
3. Guideline support for anti-inflammatory reliever therapy
SYMBICORT has benefited significantly from evolving asthma treatment guidelines favoring ICS/formoterol-based maintenance-and-reliever therapy (MART/SMART approach). The combination of rapid-acting formoterol and inhaled corticosteroid allows SYMBICORT to function both as maintenance and reliever therapy in selected asthma populations. This differentiated positioning helped sustain physician preference even amid increasing competition from generic budesonide/formoterol products. AstraZeneca has actively invested in clinical programs supporting this treatment paradigm.
4. Strong historical blockbuster sales and franchise durability
SYMBICORT historically generated multi-billion-dollar annual global sales and became one of AstraZeneca’s most important respiratory brands. Although U.S. generic entry has moderated growth, the product still maintains substantial prescription volume due to physician familiarity, established reimbursement pathways, and decades of real-world safety experience. Continued utilization in international markets and institutional settings supports durable residual revenue streams. AstraZeneca’s broader respiratory portfolio—including SYMBICORT, BREZTRI, and AIRSUPRA—continues contributing materially to company growth expectations for 2025 and beyond.
5. Affordability initiatives supporting continued patient access
In 2024, AstraZeneca announced a US$35 monthly cap on inhaler out-of-pocket costs in the U.S. for eligible uninsured and underinsured patients, including SYMBICORT. The company also reduced the list price of SYMBICORT in response to affordability concerns and increasing policy scrutiny around inhaler pricing. These initiatives may help preserve prescription volumes and improve long-term patient adherence despite increasing generic competition. Community discussions among asthma patients suggest affordability improvements could positively influence continued use of SYMBICORT among previously cost-constrained patients.
SYMBICORT Recent Developments
The drug is FDA approved for asthma maintenance & COPD; budesonide 160mcg/formoterol 4.5mcg (2 inhalations twice daily); AstraZeneca; marketed as pressurized inhalation aerosol & TurboHaler.
“SYMBICORT Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SYMBICORT for approved indication like Asthma and Chronic obstructive pulmonary disease in the 7MM. A detailed picture of SYMBICORT’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SYMBICORT for approved indications. The SYMBICORT market report provides insights about SYMBICORT’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SYMBICORT performance, future market assessments inclusive of the SYMBICORT market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SYMBICORT sales forecasts, along with factors driving its market.
SYMBICORT Drug Summary
SYMBICORT is a combination inhalation therapy developed by AstraZeneca for the treatment and maintenance management of asthma and chronic obstructive pulmonary disease (COPD). The drug combines budesonide, an inhaled corticosteroid (ICS) that reduces airway inflammation, with formoterol fumarate, a long-acting beta2-agonist (LABA) that provides rapid and sustained bronchodilation. Administered via a pressurized metered-dose inhaler, SYMBICORT helps improve lung function, reduce exacerbations, and control respiratory symptoms such as wheezing, breathlessness, and coughing. The therapy is widely recognized for its efficacy in both maintenance and reliever therapy approaches in asthma, supported by extensive clinical evidence demonstrating improved disease control, reduced hospitalization risk, and enhanced quality of life in patients with chronic respiratory diseases. The report provides SYMBICORT’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the SYMBICORT Market Report
The report provides insights into:
• A comprehensive product overview including the SYMBICORT MoA, description, dosage and administration, research and development activities in approved indication like Asthma and Chronic obstructive pulmonary disease.
• Elaborated details on SYMBICORT regulatory milestones and other development activities have been provided in SYMBICORT market report.
• The report also highlights SYMBICORT‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The SYMBICORT market report also covers the patents information, generic entry and impact on cost cut.
• The SYMBICORT market report contains current and forecasted SYMBICORT sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SYMBICORT market report also features the SWOT analysis with analyst views for SYMBICORT in approved indications.
Methodology
The SYMBICORT market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SYMBICORT Analytical Perspective by DelveInsight
• In-depth SYMBICORT Market Assessment
This SYMBICORT sales market forecast report provides a detailed market assessment of SYMBICORT for approved indication like Asthma and Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SYMBICORT sales data uptil 2034.
• SYMBICORT Clinical Assessment
The SYMBICORT market report provides the clinical trials information of SYMBICORT for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
SYMBICORT Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
SYMBICORT Market Potential & Revenue Forecast
• Projected market size for the SYMBICORT and its key indications
• Estimated SYMBICORT sales potential (SYMBICORT peak sales forecasts)
• SYMBICORT Pricing strategies and reimbursement landscape
SYMBICORT Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• SYMBICORT Market positioning compared to existing treatments
• SYMBICORT Strengths & weaknesses relative to competitors
SYMBICORT Regulatory & Commercial Milestones
• SYMBICORT Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
SYMBICORT Clinical Differentiation
• SYMBICORT Efficacy & safety advantages over existing drugs
• SYMBICORT Unique selling points
SYMBICORT Market Report Highlights
• In the coming years, the SYMBICORT market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SYMBICORT companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SYMBICORT’s dominance.
• Other emerging products for Asthma and Chronic obstructive pulmonary disease are expected to give tough market competition to SYMBICORT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SYMBICORT in approved indications.
• Analyse SYMBICORT cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SYMBICORT sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SYMBICORT in approved indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of SYMBICORT? How strong is SYMBICORT’s clinical and commercial performance?
• What is SYMBICORT’s clinical trial status in each individual indications such as Asthma and Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SYMBICORT Manufacturers?
• What are the key designations that have been granted to SYMBICORT for approved indications? How are they going to impact SYMBICORT’s penetration in various geographies?
• What is the current and forecasted SYMBICORT market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SYMBICORT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SYMBICORT for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is SYMBICORT? What is the duration of therapy and what are the geographical variations in cost per patient?
